Project 1: Hypoxia and metabolic dysregulation as a targetable barrier to immunotherapy in head and neck squamous cell carcinoma (HNSCC)
项目 1:缺氧和代谢失调作为头颈鳞状细胞癌 (HNSCC) 免疫治疗的目标障碍
基本信息
- 批准号:10331957
- 负责人:
- 金额:$ 31.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-07-01 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAffectAftercareAmerican Society of Clinical OncologyAnimalsAutomobile DrivingAwardCell physiologyCellsClinicalClinical ResearchClinical TrialsClinical Trials DesignCombination immunotherapyDataDevelopmentDiseaseEnvironmentEquilibriumExhibitsFunctional disorderFutureGoalsHead and Neck CancerHead and Neck Squamous Cell CarcinomaHypoxiaImageImmuneImmune checkpoint inhibitorImmunityImmunologicsImmunotherapyLeadMalignant NeoplasmsMetabolicMetabolismMetastatic/RecurrentMetforminMinorityModelingNivolumabOutcomeOxidative PhosphorylationPatientsPharmaceutical PreparationsPhenotypePre-Clinical ModelRecurrenceReproduction sporesResearchResearch PersonnelResistanceSamplingScanningT-LymphocyteTestingTherapeutic Clinical TrialTissuesTumor ImmunityTumor-infiltrating immune cellsX-Ray Computed Tomographyanti-CTLA4anti-PD-1anti-PD1 therapybasecell typecheckpoint inhibitioncombinatorialdesignimmune checkpoint blockadeimmunotherapy trialsimprovedinhibitorinsightipilimumabnext generationnovelnovel therapeuticspatient populationpembrolizumabpersonalized immunotherapypre-clinicalpredicting responseprogrammed cell death protein 1programsradiomicsreceptorrecruitresistance mechanismresponserosiglitazonestandard of caretargeted treatmenttranscriptome sequencingtumortumor hypoxiatumor metabolismtumor microenvironment
项目摘要
PROJECT SUMMARY − PROJECT 1
In recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC), immune checkpoint
blockade has changed the standard of care, with trials from HN SPORE PI Dr. Robert Ferris and co-I (Project
2) Dr. Barbara Burtness pioneering the use of anti-PD-1 in this setting. Unfortunately, only a minority of
patients benefit, due to resistance to anti-PD-1 therapy, pointing to an urgent need to better understand the
tumor microenvironment. With HN SPORE support, first through a Developmental Research Program award
and later following elevation to Continuing Project 1, we have identified a connection between tumor
metabolism, hypoxia and T cell dysfunction that may be partially driving resistance to anti-PD-1 (Zandberg, et
al, ASCO 2020). To further investigate this question, we are proposing to conduct two newly designed, novel
therapeutic clinical trials within Project 1, in R/M HNSCC naïve to anti-PD-1 (HCC 18-190/NCT04114136) or
progressed on anti-PD-1 (HCC 18-156/NCT04326257). The former is a trial of metabolic modulators and anti-
PD1, the latter a trial of anti-PD-1 combined with either anti-CTLA4 or anti-LAG3. Utilizing these trials and pre-
clinical models of HNSCC, we will examine the following questions. First, what is the relationship between
anti-PD-1 resistance, tumor metabolism and hypoxia in HNSCC? With the assistance of Core B, we will
address this question via multiplexed tissue analysis in R/M HNSCC samples from our clinical trials as well as
radiomics-based approaches of determining tumor hypoxia. Second, does hypoxia promote resistance to
combinatorial immunotherapy in HNSCC? We will test how hypoxia may impede immunotherapy with
nivolumab plus relatlimab (anti-LAG3), or ipilimumab (anti-CTLA4) in R/M HNSCC patients who have
progressed on anti-PD-1, evaluating tissue before and after therapy. Third, can metabolically targeted therapy
be combined with anti-PD-1 to overcome anti-PD1 resistance in HNSCC? We will evaluate tumor samples
obtained before and after treatment with anti-PD-1 plus either metformin or rosiglitazone and determine
changes in tumor metabolism and hypoxia. We will also test combinatorial immunotherapy (as in Aim 2) with
metabolic modulation in pre-clinical HNSCC models rendered anti-PD1 resistant. Our trial of metabolic
inhibitors combined with anti-PD1 therapy, if positive, will directly lead to larger scale clinical studies, opening
up an entirely novel avenue of combinatorial immunotherapy; while the project as a whole will also provide a
platform for developing future personalized immunotherapy trials by adding metabolic analysis and/or
modulation as a component.
项目摘要 - 项目1
在复发和转移性的头和颈部鳞状细胞癌(R/M HNSCC)中,免疫切口点
盖废包已改变了护理标准,并接受了HN Spore Pi Robert Ferris博士和Co-I的试验(Project
2)芭芭拉·伯特尼斯(Barbara Burtness)博士在这种情况下开创了抗PD-1的使用。不幸的是,只有少数
由于对抗PD-1疗法的抵抗,患者受益,这表明迫切需要更好地了解
肿瘤微环境。在HN孢子的支持下,首先要通过发展研究计划奖
后来在持续项目1的海拔后,我们已经确定了肿瘤之间的联系
代谢,缺氧和T细胞功能障碍可能部分推动抗PD-1的抗性(Zandberg,ET
Al,ASCO 2020)。为了进一步调查这个问题,我们提议进行两个新设计的新型新颖
项目1中的治疗临床试验,r/m hnscc天真的抗PD-1(HCC 18-190/NCT04114136)或
在抗PD-1(HCC 18-156/NCT04326257)上进行进展。前者是代谢调节剂和抗 - 的试验
PD1,后者是抗PD-1的试验,结合了抗CTLA4或抗LAG3。利用这些试验和预先
HNSCC的临床模型,我们将研究以下问题。首先,是什么关系
HNSCC中的抗PD-1耐药性,肿瘤代谢和缺氧?在核心B的帮助下,我们将
通过我们的临床试验中的R/M HNSCC样品中的多路复用组织分析解决此问题
确定肿瘤缺氧的基于放射学的方法。其次,缺氧会促进对
HNSCC中的组合免疫疗法?我们将测试缺氧如何阻止免疫疗法
nivolumab加Relatlimab(抗LAG3)或ipilimumab(抗CTLA4)的R/M HNSCC患者
在抗PD-1上进展,在治疗前后评估组织。第三,可以代谢靶向治疗
与抗PD-1结合以克服HNSCC中的抗PD1抗性?我们将评估肿瘤样品
用抗PD-1加二甲双胍或罗格列酮在治疗前后获得,并确定
肿瘤代谢和缺氧的变化。我们还将与
临床前HNSCC模型中的代谢调节具有抗PD1的抗性。我们的代谢试验
抑制剂结合抗PD1治疗(如果阳性)将直接导致更大的临床研究,开放
建立一条完全新颖的组合免疫疗法途径;虽然整个项目也将提供
通过添加代谢分析和/或
调制为组件。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Greg M. Delgoffe其他文献
Redox and detox: Malate shuttle metabolism keeps exhausted T cells fit.
氧化还原和排毒:苹果酸穿梭代谢使疲惫的 T 细胞保持健康。
- DOI:
10.1016/j.cmet.2023.11.005 - 发表时间:
2023 - 期刊:
- 影响因子:29
- 作者:
Alok Kumar;Greg M. Delgoffe - 通讯作者:
Greg M. Delgoffe
Regulatory T cell stability is maintained by a neuropilin-1 : semaphorin-4 a axis
调节性 T 细胞的稳定性由 Neuropilin-1 : semaphorin-4 a 轴维持
- DOI:
- 发表时间:
2016 - 期刊:
- 影响因子:0
- 作者:
Greg M. Delgoffe;Seng;Meghan E. Turnis;D. Gravano;C. Guy;Abigail E. Overacre;M. Bettini;P. Vogel;D. Finkelstein;Jody;Bonnevier;C. Workman;D. Vignali - 通讯作者:
D. Vignali
The intrinsic pro-tumorigenic role of IRF1
IRF1 的内在促肿瘤作用
- DOI:
- 发表时间:
2018 - 期刊:
- 影响因子:4.4
- 作者:
Lulu Shao;W. Hou;Nicole E. Scharping;Greg M. Delgoffe;Saumendra N. Sarkar - 通讯作者:
Saumendra N. Sarkar
670 Oxidative stress originating in the mitochondria damages telomeres sufficient to drive certain features of T cell dysfunction
第670章 起源于线粒体的氧化应激会损害端粒,足以驱动T细胞功能障碍的某些特征
- DOI:
- 发表时间:
2021 - 期刊:
- 影响因子:10.9
- 作者:
Dayana B Rivadeneira;Jess Yana;Sanjana A Thosar;M. Bruchez;Patricia Lynn;Greg M. Delgoffe - 通讯作者:
Greg M. Delgoffe
Altered costimulatory signals and hypoxia support chromatin landscapes limiting the functional potential of exhausted T cells in cancer
共刺激信号的改变和缺氧支持染色质景观限制了癌症中耗尽的 T 细胞的功能潜力
- DOI:
10.1101/2021.07.11.451947 - 发表时间:
2021 - 期刊:
- 影响因子:0
- 作者:
B. R. Ford;Natalie L. Rittenhouse;Nicole E. Scharping;Paolo D. A. Vignali;A. Frisch;Ronal M. Peralta;Greg M. Delgoffe;Amanda C. Poholek - 通讯作者:
Amanda C. Poholek
Greg M. Delgoffe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Greg M. Delgoffe', 18)}}的其他基金
Dissecting the role of hypoxia in T cell differentiation in cancer
剖析缺氧在癌症 T 细胞分化中的作用
- 批准号:
10578000 - 财政年份:2023
- 资助金额:
$ 31.71万 - 项目类别:
Metabolic control of regulatory T cell functional identity
调节性 T 细胞功能特性的代谢控制
- 批准号:
10510537 - 财政年份:2022
- 资助金额:
$ 31.71万 - 项目类别:
Uncovering the metabolic underpinnings of T cell exhaustion
揭示 T 细胞耗竭的代谢基础
- 批准号:
10707255 - 财政年份:2022
- 资助金额:
$ 31.71万 - 项目类别:
Metabolic control of regulatory T cell functional identity
调节性 T 细胞功能特性的代谢控制
- 批准号:
10677731 - 财政年份:2022
- 资助金额:
$ 31.71万 - 项目类别:
Uncovering the metabolic underpinnings of T cell exhaustion
揭示 T 细胞耗竭的代谢基础
- 批准号:
10593593 - 财政年份:2022
- 资助金额:
$ 31.71万 - 项目类别:
Exploring and exploiting metabolic plasticity in regulatory T cells
探索和利用调节性 T 细胞的代谢可塑性
- 批准号:
9348845 - 财政年份:2017
- 资助金额:
$ 31.71万 - 项目类别:
Elucidating the regulation of interleukin-35, a regulatory cytokine, in T cells
阐明 T 细胞中调节性细胞因子 IL-35 的调节
- 批准号:
8610875 - 财政年份:2012
- 资助金额:
$ 31.71万 - 项目类别:
Elucidating the regulation of interleukin-35, a regulatory cytokine, in T cells
阐明 T 细胞中调节性细胞因子 IL-35 的调节
- 批准号:
8255282 - 财政年份:2012
- 资助金额:
$ 31.71万 - 项目类别:
Elucidating the regulation of interleukin-35, a regulatory cytokine, in T cells
阐明 T 细胞中调节性细胞因子 IL-35 的调节
- 批准号:
8432601 - 财政年份:2012
- 资助金额:
$ 31.71万 - 项目类别:
Project 1: Hypoxia and metabolic dysregulation as a targetable barrier to immunotherapy in head and neck squamous cell carcinoma (HNSCC)
项目 1:缺氧和代谢失调作为头颈鳞状细胞癌 (HNSCC) 免疫治疗的目标障碍
- 批准号:
10704505 - 财政年份:2004
- 资助金额:
$ 31.71万 - 项目类别:
相似国自然基金
面向康复护理机器人的人机信任度评估方法与任务影响机制研究
- 批准号:62306195
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
长期护理保险制度与老年照护供给效率及公平:影响机制与政策措施
- 批准号:72274117
- 批准年份:2022
- 资助金额:45.00 万元
- 项目类别:面上项目
长期护理保险制度与老年照护供给效率及公平:影响机制与政策措施
- 批准号:
- 批准年份:2022
- 资助金额:45 万元
- 项目类别:面上项目
深海土阻力时变特性影响下管线轴向走管的变形机理及防护理论研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
深海土阻力时变特性影响下管线轴向走管的变形机理及防护理论研究
- 批准号:52101325
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
相似海外基金
Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
- 批准号:
10456380 - 财政年份:2023
- 资助金额:
$ 31.71万 - 项目类别:
Implementing Evidence-Based Treatment for Common Mental Disorders in HIV Clinics in Ukraine
在乌克兰艾滋病毒诊所对常见精神疾病实施循证治疗
- 批准号:
10762576 - 财政年份:2023
- 资助金额:
$ 31.71万 - 项目类别:
Anxiety in Youth with Autism Spectrum Disorder
自闭症谱系障碍青少年的焦虑
- 批准号:
10784337 - 财政年份:2023
- 资助金额:
$ 31.71万 - 项目类别:
Accelerated Neuromodulation of Prefrontal Circuitry during Clozapine Treatment
氯氮平治疗期间前额叶回路的加速神经调节
- 批准号:
10726660 - 财政年份:2023
- 资助金额:
$ 31.71万 - 项目类别:
Targeting adolescent depression symptoms using network-based real-time fMRI neurofeedback and mindfulness meditation
使用基于网络的实时功能磁共振成像神经反馈和正念冥想针对青少年抑郁症状
- 批准号:
10581837 - 财政年份:2023
- 资助金额:
$ 31.71万 - 项目类别: